Avenue Therapeutics
Manufacturing · Florida, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
1111 Kane Concourse Ste 301, Bay Harbor ...Phone Number
(781) 652-4500Website
www.avenuetx.comRevenue
$11.8 MillionStock Symbol
ATXIIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Avenue Therapeutics
Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City.Explore more
Avenue Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Avenue Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Avenue Therapeutics launches new products
Check out if Avenue Therapeutics is spiking on competitors!
Avenue Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Avenue Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Avenue Therapeutics recently announced quarterly report
Click to see if Avenue Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Avenue Therapeutics
Funding: Get notified immidiatlly once Avenue Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Avenue Therapeutics
Compare insights from companies similar to Avenue Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Avenue Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Avenue Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Avenue Therapeutics.
Avenue Therapeutics financials insights
Gather financial insights about Avenue Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Stock Offering
$33M
Avenue Therapeutics Tech Stack
A closer look at the technologies used by Avenue Therapeutics
See more technologies
Most Recent Scoops
Earnings
Earnings, Finance
Left Company
Executive Move
Executive Moves, Left Company
Earnings
Earnings
Product Management
Earnings
Avenue Therapeutics News & Media
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from Axsome Baergic shareholders eligible to receive up to approximately $82 million in potential development, regulatory, and sales milestones plus a tiered mid-to-high single digit royalty on global net sales from AxsomeAvenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
- Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024 - Topline data in Phase 1b/2a clinical trial of AJ201 for spinal and bulbar muscular atrophy anticipated around year-end 2024Avenue Therapeutics to Participate in Maxim Group’s 2024 Healthcare Virtual Summit
MIAMI, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in a fireside chat at Maxim Group’s 2024 Healthcare Virtual Summit on Tuesday, October 15, 2024 at 1:30 PM ET.Avenue Therapeutics to Participate in Upcoming Investor Conferences
MIAMI, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer of Avenue Therapeutics, will participate in the following upcoming investor conferences:
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Avenue Therapeutics
Sign Up For FreeTo access detailed company insights
Avenue Therapeutics is a specialty pharmaceutical company whose mission is to develop IV tramadol, a potential alternative that could reduce the use of conventional opioids, for patients suffering from acute pain in the U.S. Avenue is headquartered in New York City.... Read More
